Abivax’s (ABVX) “Buy” Rating Reaffirmed at BTIG Research

Abivax (NASDAQ:ABVX)‘s stock had its “buy” rating reaffirmed by investment analysts at BTIG Research in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $150.00 price target on the stock. BTIG Research’s price objective suggests a potential upside of 15.66% from the company’s previous close.

Several other equities analysts have also recently commented on ABVX. Wall Street Zen upgraded Abivax from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research note on Monday, April 20th. Wedbush started coverage on Abivax in a research note on Tuesday, February 24th. They set an “outperform” rating and a $110.00 target price for the company. Citigroup restated an “outperform” rating on shares of Abivax in a research note on Tuesday. Finally, Citizens Jmp restated a “market outperform” rating and set a $131.00 price objective on shares of Abivax in a research note on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $131.77.

Abivax Trading Down 2.2%

Abivax stock opened at $129.69 on Tuesday. The stock has a market cap of $10.33 billion, a P/E ratio of -24.89 and a beta of 0.69. The stock has a 50 day moving average of $118.57 and a 200-day moving average of $120.16. Abivax has a 52 week low of $5.69 and a 52 week high of $148.83.

Abivax (NASDAQ:ABVX) last released its earnings results on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.23. The business had revenue of $1.56 million for the quarter, compared to analysts’ expectations of $0.40 million. As a group, equities analysts predict that Abivax will post -3.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Avidity Partners Management LP acquired a new position in Abivax during the first quarter worth about $1,114,000. Bank of America Corp DE grew its holdings in Abivax by 40.9% during the first quarter. Bank of America Corp DE now owns 735,729 shares of the company’s stock worth $81,923,000 after acquiring an additional 213,440 shares during the period. Janus Henderson Group PLC grew its holdings in Abivax by 31.6% during the first quarter. Janus Henderson Group PLC now owns 878,829 shares of the company’s stock worth $98,007,000 after acquiring an additional 211,068 shares during the period. Oddo BHF Asset Management Sas grew its holdings in Abivax by 2.7% during the first quarter. Oddo BHF Asset Management Sas now owns 81,496 shares of the company’s stock worth $9,075,000 after acquiring an additional 2,146 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new position in Abivax during the first quarter worth about $278,000. 47.91% of the stock is owned by institutional investors and hedge funds.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.